<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233879</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-020</org_study_id>
    <secondary_id>MK-8591A-020</secondary_id>
    <secondary_id>2019-000590-23</secondary_id>
    <nct_id>NCT04233879</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)</brief_title>
  <official_title>A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, controlled, double-blind clinical study of a once-daily fixed
      dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL [also known as
      MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type-1 (HIV-1)
      infection. The primary hypothesis is that DOR/ISL is non-inferior to
      bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) treatment based on the
      percentage of participants with HIV-1 ribonucleic acid (RNA) &lt;50 copies/mL at Week 48.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies/mL will be determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing from study treatment due to AE(s)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;200 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;200 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 48</time_frame>
    <description>CD4+ T-cell counts will be measured by a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 96</time_frame>
    <description>CD4+ T-cell counts will be measured by a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral resistance-associated substitutions (RASs)</measure>
    <time_frame>Week 48</time_frame>
    <description>The incidence of viral RASs will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral RASs</measure>
    <time_frame>Week 96</time_frame>
    <description>The incidence of viral RASs will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day 1 (baseline) and Week 48</time_frame>
    <description>The change from baseline in participant body weight will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day 1 (baseline) and Week 96</time_frame>
    <description>The change from baseline in participant body weight will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants with HIV-1 receive DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) for 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment-naïve participants with HIV-1 receive BIC/FTC/TAF and placebo to DOR/ISL QD for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR/ISL</intervention_name>
    <description>100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.</description>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
    <other_name>MK-8591A</other_name>
    <other_name>Doravirine/islatravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC/FTC/TAF</intervention_name>
    <description>BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.</description>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
    <other_name>Bictegravir/emtricitabine/tenofovir alafenamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BIC/FTC/TAF</intervention_name>
    <description>Placebo tablet matched to BIC/FTC/TAF taken by mouth.</description>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to DOR/ISL</intervention_name>
    <description>Placebo tablet matched to DOR/ISL taken by mouth.</description>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is HIV-1 positive

          -  Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior
             therapy with any antiretroviral agent following a diagnosis of HIV-1 infection
             including prevention of mother-to-child transmission up to 1 month prior to screening.

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and at least one of the following conditions applies: 1) Is not a woman
             of childbearing potential (WOCBP); 2) Is a WOCBP and using an acceptable contraceptive
             method, or be abstinent from heterosexual intercourse as their preferred and usual
             lifestyle (abstinent on a long term and persistent basis); 3) A WOCBP must have a
             negative highly sensitive pregnancy test ([urine or serum] as required by local
             regulations) within 24 hours before the first dose of study intervention; 4) If a
             urine test cannot be confirmed as negative (eg, an ambiguous result), a serum
             pregnancy test is required

        Exclusion Criteria:

          -  Has HIV-2 infection

          -  Has hypersensitivity or other contraindication to any of the components of the study
             interventions as determined by the investigator

          -  Has an active diagnosis of hepatitis due to any cause, including active HBV infection
             (defined as hepatitis B surface antigen [HBsAg]-positive or hepatitis B virus
             deoxyribonucleic acid [HBV DNA]-positive)

          -  Has a history of malignancy ≤5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
             or cutaneous Kaposi's sarcoma

          -  Has a history or current evidence of any condition (including active tuberculosis
             infection), therapy, laboratory abnormality or other circumstance (including drug or
             alcohol use or dependence) that might, in the opinion of the investigator, confound
             the results of the study or interfere with the participant's participation for the
             full duration of the study

          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
             agent that is active against HIV-1

          -  Is taking or is anticipated to require systemic immunosuppressive therapy, immune
             modulators, or any prohibited therapy from 45 days prior to Day 1 through the study
             intervention period

          -  Is currently participating in or has participated in a clinical study with an
             investigational compound or device from 45 days prior to Day 1 through the study
             intervention period

          -  Has a documented or known virologic resistance to any approved HIV-1 reverse
             transcriptase inhibitor, or any study intervention

          -  Has exclusionary laboratory values within 45 days prior to Day 1

          -  Is female and is expecting to conceive or donate eggs at any time during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-975-4285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pueblo Family Physicians ( Site 5606)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-999-6495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group, Inc. ( Site 5624)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-954-0400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research ( Site 5622)</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>772-519-0642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC ( Site 5625)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-330-9977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group ( Site 5615)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-497-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 5613)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAN Community Health ( Site 5627)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941366013411102</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 5621)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health ( Site 5616)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-321-0495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists Of Atlanta PC ( Site 5608)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-297-9755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City CARE Clinic ( Site 5607)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-777-2757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 5630)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-349-8092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 5629)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-839-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas ID Consultants, PA ( Site 5604)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-276-5618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates P.A. ( Site 5619)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>817-348-0042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network ( Site 5705)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4163404800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale L Actuel ( Site 5714)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5145243642271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 5905)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56996420376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 5900)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992280653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arriaran ( Site 5901)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998205294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux. Hopital Pellegrin ( Site 6116)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795523</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 6100)</name>
      <address>
        <city>Tourcoing</city>
        <state>Nord</state>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320694617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 6102)</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33148955146</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 6114)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere ( Site 6111)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0142160142</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 6124)</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 6301)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934656374162</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 6300)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz ( Site 6307)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+915504800</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

